StockNews.com Initiates Coverage on Check-Cap (NASDAQ:CHEK)

StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report released on Saturday morning. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Trading Down 23.7 %

Shares of NASDAQ CHEK opened at $1.35 on Friday. The firm has a market cap of $7.90 million, a P/E ratio of -0.45 and a beta of 0.17. The business’s 50 day moving average is $0.96 and its 200-day moving average is $1.49. Check-Cap has a 1-year low of $0.56 and a 1-year high of $3.45.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.